Lymphoma, Non-Hodgkin
322
27
51
178
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
94 trials with published results (29%)
Research Maturity
178 completed trials (55% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
15.8%
51 terminated out of 322 trials
77.7%
-8.8% vs benchmark
8%
27 trials in Phase 3/4
53%
94 of 178 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 178 completed trials
Clinical Trials (322)
A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Tissue Collection for Studies of Lymph Cancer
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
Primary Bone Mature B-Cell NHL in Children
A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO Study
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies